1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,156 | 0,177 | 03.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.10. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT FIRST COHORT OF HEALTHY SUBJECTS DOSED WITH SUBCUTANEOUS FORMULATION OF SM17 IN A BRIDGING STUDY IN CHINA | - | HKEx | ||
| 08.10. | SINOMAB BIO-B (03681): CHANGE OF COMPANY SECRETARY | 1 | HKEx | ||
| 26.09. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 2 | HKEx | ||
| 26.09. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | - | HKEx | ||
| 26.09. | SINOMAB BIO-B (03681): INTERIM REPORT 2025 | - | HKEx | ||
| 29.08. | SINOMAB BIO-B (03681): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025 | - | HKEx | ||
| SINOMAB BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 29.08. | SINOMAB BIO-B (03681): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 29.08. | SINOMAB BIO-B (03681): COMPLETION OF SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE | - | HKEx | ||
| 18.08. | SINOMAB BIO-B (03681): DATE OF BOARD MEETING | 1 | HKEx | ||
| 15.08. | SINOMAB BIO-B (03681): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 15.08. | SINOMAB BIO-B (03681): COMPLETION OF CERTAIN SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 12.08. | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT COMPREHENSIVE STRATEGIC COOPERATION AGREEMENT | 1 | HKEx | ||
| 24.07. | SINOMAB BIO-B (03681): GRANT OF SHARE OPTIONS | 1 | HKEx | ||
| 22.07. | SINOMAB BIO-B (03681): SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE | 3 | HKEx | ||
| 14.07. | SINOMAB BIO-B (03681): INSIDE INFORMATION UPDATE ON THE BLA FOR SM03 (SUCIRASLIMAB) IN THE TREATMENT OF RHEUMATOID ARTHRITIS | - | HKEx | ||
| 30.06. | SINOMAB BIO-B (03681): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE ADOPTED BY THE BOARD ON 30 JUNE, 2025 | 1 | HKEx | ||
| 30.06. | SINOMAB BIO-B (03681): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 30.06. | SINOMAB BIO-B (03681): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 30 JUNE 2025, APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS, CHANGE IN ... | - | HKEx | ||
| 12.06. | SINOMAB BIO-B (03681): RESIGNATION OF EXECUTIVE DIRECTOR | - | HKEx | ||
| 11.06. | SINOMAB BIO-B (03681): POSTPONEMENT AND CHANGE OF VENUE OF ANNUAL GENERAL MEETING AND CHANGE OF BOOK CLOSURE PERIOD | 1 | HKEx |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 186,15 | +4,02 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VERA THERAPEUTICS | 41,260 | +10,77 % | Why Vera Therapeutics Stock Rocked the Market on Tuesday | ||
| NUVALENT | 106,90 | 0,00 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,960 | +1,80 % | Mizuho raises Arcutis Biotherapeutics stock price target on strong Zoryve sales | ||
| BEAM THERAPEUTICS | 26,740 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 39,200 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 39,920 | -1,20 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| JANUX THERAPEUTICS | 17,110 | 0,00 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| CG ONCOLOGY | 42,610 | 0,00 % | CG Oncology appoints Christina Rossi to board of directors | ||
| SUMMIT THERAPEUTICS | 18,370 | 0,00 % | Don't Buy Summit Therapeutics Until This Big Thing Happen | ||
| NURIX THERAPEUTICS | 16,830 | +2,94 % | Nurix to host webcast on bexobrutideg clinical data next week | ||
| AVIDITY BIOSCIENCES | 71,58 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| DISC MEDICINE | 92,38 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner's National Priority Voucher... ► Artikel lesen | |
| IMMUNOME | 19,370 | 0,00 % | Truist Securities initiates coverage on Immunome stock with Buy rating | ||
| RECURSION PHARMACEUTICALS | 4,665 | 0,00 % | Recursion Pharmaceuticals registriert Aktienpaket für Wiederverkauf durch Tempus AI |
SINOMAB BIOSCIENCE LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,198 Euro und damit +16,47 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SINOMAB BIOSCIENCE LTD finden Sie auf Wallstreet Online.